This paper is only available as a PDF. To read, Please Download here.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Excitotoxin lesions do not mimic the alteration of somatostatin in Huntington's disease.Brain Res. 1985; 361: 135-145
- Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid.Nature. 1986; 321: 168-171
- Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions.Synapse. 1989; 31: 38-47
- Kynurenine pathway measurements in Huntington's disease striatum: Evidence for reduced formation of kynurenic acid.J Neurochem. 1990; 55: 1327-1339
- Neurochemistry and toxin models in Huntington's disease.Curr Opin Neurol. 1994; 7: 542-547
- Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea.Nature. 1976; 263: 244-246
- Conduct disorder and affective disorder among the offspring of patients with Huntington's disease.Psychol Med. 1983; 13: 45-52
- The association of affective disorder with Huntington's disease in a case series and in families.Psychol Med. 1993; 13: 537-542
- A primate model of Huntington's disease: Behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon.Exp Neurol. 1990; 108: 91-104
- Tryptophan metabolism I: Concerning the mechanism of the mammalian conversation of tryptophan into kynurenine, kynurenic acid and nicotinic acid.J Biol Chem. 1949; 179: 143-150
- Comparison of ibotenate and kainate neurotoxicity in rat brain.Neuroscience. 1983; 8: 819-835
- Huntington's disease.N Engl J Med. 1986; 315: 1267-1276
- Duplication of biochemical changes of Huntington's chorea by intrastriatal injection of glutamic and kainic acids.Nature. 1976; 263: 517-519
- Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats.J Cerebral Blood Flow Metabol. 1992; 12: 400-407
- Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease.Gerontology. 1977; 23: 55-63
- The quinolinic acid model of Huntington's disease: Locomotor abnormalities.Exp Neurol. 1989; 105: 45-53
- Quinolinic acid: An endogenous metabolite that produces axon-sparing lesion in rat brain.Science. 1983; 219: 316-318
- Excitotoxic models of neurodegenerative disorders.Life Sci. 1984; 35: 19-32
- Quinolinic acid and other kynurenines in the central nervous system.Neuroscience. 1985; 15: 597-617
- Neuropharmacology of quinolinic and kynurenic acids.Pharmacol Rev. 1993; 45: 309-379
- Movement disorder following excitotoxin lesions in primates.NeuroReport. 1994; 5: 1259-1261
- Influence of kynurenine treatment on open-field activity, elevated plus maze, avoidance behaviors and seizures in rats.Pharmacol Biochem Behav. 1990; 37: 71-76
- Intracerebroventricular injection of kynurenic acid, but not kynurenine, induces ataxia and stereotyped behavior in rats.Brain Res Bull. 1990; 25: 623-627
- Comparative behavioral and neurochemical studies with striatal kainic acid or quinolinic acid lesioned rats.Pharmacol Biochem Behav. 1991; 39: 473-478
- Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats.Eur J Pharmacol. 1991; 196: 239-246
- Behavioral and pharmacological effects of centrally administered aminooxyacetic acid in rats.Eur J Pharmacol. 1992; 220: 259-262
- Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain.Brain Res Bull. 1992; 28: 233-238
- Effects of kynurenine and probenecid on plasma and brain tissue concentrations of kynurenic acid.Neurodegeneration. 1992; 1: 17-26
- Neurological Disorders: Novel Experimental and Therapeutic Strategies.Ellis Horwood, New York1992
Article info
Publication history
Received in revised form:
July 7,
1995
Received:
February 2,
1995
Footnotes
Our experiments referred to in this paper were performed at the Laboratory of Neurochemistry, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Identification
Copyright
© 1996 Society of Biological Psychiatry. Published by Elsevier Inc.
